NASDAQ:IMGN - ImmunoGen Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$10.43 -0.15 (-1.42 %)
(As of 05/25/2018 04:00 PM ET)
Previous Close$10.58
Today's Range$10.17 - $10.54
52-Week Range$4.26 - $13.41
Volume1.46 million shs
Average Volume2.97 million shs
Market Capitalization$1.38 billion
P/E Ratio-13.93
Dividend YieldN/A
Beta2.17

About ImmunoGen (NASDAQ:IMGN)

ImmunoGen logoImmunoGen, Inc., a clinical-stage biotechnology company, focuses on developing antibody-drug conjugate (ADC) therapies to treat cancer. Its product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha, which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; IMGN779 that is in Phase I clinical trial for the treatment of acute myeloid leukemia (AML); and IMGN632, a CD123-targeting ADC that is in Phase I clinical trial for treating AML and blastic plasmacytoid dendritic cell neoplasm, as well as coltuximab ravtansine, a CD19-targeting ADC, which is in Phase II trial for DLBCL. ImmunoGen, Inc. has collaborations with Roche; Bayer HealthCare AG; Sanofi; Biotest AG; Novartis Institutes for BioMedical Research, Inc.; Eli Lilly and Company; Amgen; CytomX Therapeutics, Inc.; Takeda Pharmaceutical Company Limited; Jazz Pharmaceuticals plc; and Debiopharm International SA. ImmunoGen, Inc. was founded in 1981 and is headquartered in Waltham, Massachusetts.

Receive IMGN News and Ratings via Email

Sign-up to receive the latest news and ratings for IMGN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:IMGN
CUSIP45253H10
Phone781-895-0600

Debt

Debt-to-Equity Ratio-0.06
Current Ratio3.74
Quick Ratio3.73

Price-To-Earnings

Trailing P/E Ratio-13.93
Forward P/E Ratio-9.23
P/E GrowthN/A

Sales & Book Value

Annual Sales$115.45 million
Price / Sales12.02
Cash FlowN/A
Price / CashN/A
Book Value($0.27) per share
Price / Book-38.63

Profitability

EPS (Most Recent Fiscal Year)($0.75)
Net Income$-96,010,000.00
Net Margins-109.85%
Return on EquityN/A
Return on Assets-39.05%

Miscellaneous

Employees293
Outstanding Shares133,040,000

ImmunoGen (NASDAQ:IMGN) Frequently Asked Questions

What is ImmunoGen's stock symbol?

ImmunoGen trades on the NASDAQ under the ticker symbol "IMGN."

How were ImmunoGen's earnings last quarter?

ImmunoGen (NASDAQ:IMGN) announced its quarterly earnings data on Friday, May, 4th. The biotechnology company reported ($0.30) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.27) by $0.03. The biotechnology company had revenue of $19.80 million for the quarter, compared to analyst estimates of $15.04 million. ImmunoGen's revenue was down 30.5% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.20) earnings per share. View ImmunoGen's Earnings History.

What price target have analysts set for IMGN?

8 equities research analysts have issued 1 year price targets for ImmunoGen's stock. Their predictions range from $5.00 to $20.00. On average, they anticipate ImmunoGen's stock price to reach $13.1667 in the next year. View Analyst Ratings for ImmunoGen.

What are Wall Street analysts saying about ImmunoGen stock?

Here are some recent quotes from research analysts about ImmunoGen stock:
  • 1. According to Zacks Investment Research, "ImmunoGen is heavily dependent on its lead ovarian cancer candidate, mirvetuximab soravtansine. Hence, any kind of development or a regulatory setback could hamper the stock. The ovarian cancer space being competitive is also a matter of concern for the company. On the flip side, the company has made a significant progress with mirvetuximab soravtansine. Successful development and subsequent approval of the candidate will be a huge boost to the company as the ovarian cancer market has immense potential. The company has collaborations with big healthcare companies which not only validate its technology but also provides it with funds in the form of milestone and royalty payments. However, the company’s high dependence on its partnerships for revenue is concerning. The company’s shares have outperformed the broader industry in a year's time. Estimates have been stable lately ahead of the company’s Q1 earnings release." (4/16/2018)
  • 2. Cantor Fitzgerald analysts commented, "FORWARD Progress. The nearest term commercial opportunity for IMGN is the FORWARD I trial, which is exploring mirvetuximab soravtansine (mirva") as a single agent in 3rd line ovarian cancer in women who express high levels of the FRa receptor. This trial could read out in 2019 pending completion of enrollment in 2018." (11/3/2017)
  • 3. Cowen Inc analysts commented, "IMGN announced a collaboration agreement with Jazz for the development and." (8/29/2017)

Are investors shorting ImmunoGen?

ImmunoGen saw a increase in short interest during the month of April. As of April 13th, there was short interest totalling 13,024,063 shares, an increase of 17.9% from the March 30th total of 11,049,179 shares. Based on an average daily volume of 2,202,365 shares, the short-interest ratio is currently 5.9 days. Currently, 10.0% of the company's stock are short sold.

Who are some of ImmunoGen's key competitors?

Who are ImmunoGen's key executives?

ImmunoGen's management team includes the folowing people:
  • Mr. Mark J. Enyedy, Pres, CEO & Director (Age 54)
  • Mr. David B. Johnston, Exec. VP, CFO & Principal Accounting Officer (Age 63)
  • Dr. Richard J. Gregory, Exec. VP & Chief Scientific Officer (Age 60)
  • Dr. Anna Berkenblit, VP & Chief Medical Officer (Age 48)
  • Ms. Carol Hausner, Exec. Director of Investor Relations & Corp. Communications

Has ImmunoGen been receiving favorable news coverage?

Media stories about IMGN stock have been trending somewhat positive recently, Accern Sentiment Analysis reports. The research group ranks the sentiment of press coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. ImmunoGen earned a daily sentiment score of 0.18 on Accern's scale. They also assigned press coverage about the biotechnology company an impact score of 44.78 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the next few days.

Who are ImmunoGen's major shareholders?

ImmunoGen's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Redmile Group LLC (7.29%), BlackRock Inc. (6.28%), Franklin Resources Inc. (2.01%), Wells Fargo & Company MN (1.35%), PointState Capital LP (1.26%) and Pinnacle Associates Ltd. (0.95%). Company insiders that own ImmunoGen stock include Craig Barrows, Daniel M Junius, David Brannon Johnston, Mark Alan Goldberg, Mark J Enyedy and Richard J Gregory. View Institutional Ownership Trends for ImmunoGen.

Which institutional investors are selling ImmunoGen stock?

IMGN stock was sold by a variety of institutional investors in the last quarter, including Redmile Group LLC, JPMorgan Chase & Co., Franklin Resources Inc., BlackRock Inc., Royal Bank of Canada, Guggenheim Capital LLC, Pinnacle Associates Ltd. and Stifel Financial Corp. Company insiders that have sold ImmunoGen company stock in the last year include Craig Barrows, Daniel M Junius, David Brannon Johnston, Mark J Enyedy and Richard J Gregory. View Insider Buying and Selling for ImmunoGen.

Which institutional investors are buying ImmunoGen stock?

IMGN stock was purchased by a variety of institutional investors in the last quarter, including PointState Capital LP, UBS Group AG, Wells Fargo & Company MN, Trexquant Investment LP, Summit Trail Advisors LLC, Allianz Asset Management GmbH, Allianz Asset Management GmbH and A.R.T. Advisors LLC. Company insiders that have bought ImmunoGen stock in the last two years include Craig Barrows, Mark Alan Goldberg, Mark J Enyedy and Richard J Gregory. View Insider Buying and Selling for ImmunoGen.

How do I buy shares of ImmunoGen?

Shares of IMGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is ImmunoGen's stock price today?

One share of IMGN stock can currently be purchased for approximately $10.43.

How big of a company is ImmunoGen?

ImmunoGen has a market capitalization of $1.38 billion and generates $115.45 million in revenue each year. The biotechnology company earns $-96,010,000.00 in net income (profit) each year or ($0.75) on an earnings per share basis. ImmunoGen employs 293 workers across the globe.

How can I contact ImmunoGen?

ImmunoGen's mailing address is 830 WINTER ST, WALTHAM MA, 02451. The biotechnology company can be reached via phone at 781-895-0600 or via email at [email protected]


MarketBeat Community Rating for ImmunoGen (IMGN)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  299 (Vote Outperform)
Underperform Votes:  310 (Vote Underperform)
Total Votes:  609
MarketBeat's community ratings are surveys of what our community members think about ImmunoGen and other stocks. Vote "Outperform" if you believe IMGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IMGN will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

ImmunoGen (NASDAQ:IMGN) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
8 Wall Street analysts have issued ratings and price targets for ImmunoGen in the last 12 months. Their average twelve-month price target is $13.1667, suggesting that the stock has a possible upside of 26.24%. The high price target for IMGN is $20.00 and the low price target for IMGN is $5.00. There are currently 2 hold ratings and 6 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.752.752.562.50
Ratings Breakdown: 0 Sell Rating(s)
2 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
2 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
2 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $13.1667$11.50$9.4714$8.05
Price Target Upside: 26.24% upside11.00% upside6.30% upside64.96% upside

ImmunoGen (NASDAQ:IMGN) Consensus Price Target History

Price Target History for ImmunoGen (NASDAQ:IMGN)

ImmunoGen (NASDAQ:IMGN) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/17/2018CowenReiterated RatingHoldMediumView Rating Details
5/17/2018HC WainwrightSet Price TargetBuy$18.00MediumView Rating Details
4/27/2018Canaccord GenuityReiterated RatingBuy$20.00LowView Rating Details
4/8/2018Cantor FitzgeraldSet Price TargetHold$5.00LowView Rating Details
3/26/2018Leerink SwannReiterated RatingOutperformMediumView Rating Details
3/21/2018Royal Bank of CanadaBoost Price TargetOutperform$16.00LowView Rating Details
10/12/2017Jefferies GroupReiterated RatingBuy$9.00N/AView Rating Details
6/26/2017William BlairReiterated RatingOutperformHighView Rating Details
3/1/2017Morgan StanleyLower Price TargetUnderweight$2.50 ➝ $1.30N/AView Rating Details
8/5/2016JPMorgan Chase & Co.Set Price TargetHold$9.00 ➝ $5.00N/AView Rating Details
(Data available from 5/25/2016 forward)

Earnings

ImmunoGen (NASDAQ:IMGN) Earnings History and Estimates Chart

Earnings by Quarter for ImmunoGen (NASDAQ:IMGN)

ImmunoGen (NASDAQ:IMGN) Earnings Estimates

2018 EPS Consensus Estimate: ($1.08)
2019 EPS Consensus Estimate: ($1.26)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182($0.27)($0.25)($0.26)
Q2 20182($0.28)($0.27)($0.28)
Q3 20182($0.28)($0.27)($0.28)
Q4 20182($0.28)($0.26)($0.27)
Q1 20191($0.30)($0.30)($0.30)
Q2 20191($0.30)($0.30)($0.30)
Q3 20191($0.32)($0.32)($0.32)
Q4 20191($0.34)($0.34)($0.34)

ImmunoGen (NASDAQ IMGN) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/4/2018Q1 2018($0.27)($0.30)$15.04 million$19.80 millionViewN/AView Earnings Details
2/9/2018Q4 2017($0.07)($0.10)$39.62 million$39.40 millionViewListenView Earnings Details
11/3/2017Q3 2017($0.19)($0.61)$26.09 million$8.50 millionViewN/AView Earnings Details
7/28/2017Q2 2017($0.1660)($0.10)$30.59 million$39.02 millionViewN/AView Earnings Details
5/5/20173/31/2017($0.36)($0.20)$16.16 million$28.70 millionViewN/AView Earnings Details
2/17/2017Q2 2017($0.39)($0.39)$16.28 million$13.85 millionViewListenView Earnings Details
10/28/2016Q117($0.38)($0.51)$21.12 million$7.66 millionViewListenView Earnings Details
8/4/2016Q416($0.39)($0.51)$17.11 million$7.41 millionViewListenView Earnings Details
4/29/2016Q316($0.31)($0.37)$23.02 million$19.71 millionViewListenView Earnings Details
1/29/2016Q216($0.36)($0.38)$19.54 million$18.03 millionViewListenView Earnings Details
10/27/2015Q116($0.35)($0.39)$15.84 million$14.90 millionViewListenView Earnings Details
7/31/2015Q415($0.34)($0.35)$15.42 million$12.61 millionViewListenView Earnings Details
4/24/2015Q315($0.25)($0.25)$20.95 million$11.40 millionViewListenView Earnings Details
1/30/2015Q215($0.06)$0.16$37.30 million$48.30 millionViewListenView Earnings Details
10/24/2014Q115($0.14)($0.26)$21.80 million$13.20 millionViewListenView Earnings Details
8/1/2014Q414($0.36)($0.31)$9.72 million$5.74 millionViewN/AView Earnings Details
4/25/2014Q314($0.27)($0.44)$13.28 million$6.90 millionViewN/AView Earnings Details
1/31/2014Q214($0.18)($0.29)$18.16 million$30.10 millionViewListenView Earnings Details
10/25/2013Q114($0.23)($0.13)$12.10 million$17.20 millionViewN/AView Earnings Details
8/2/2013Q4 2013($0.30)($0.26)$3.44 million$3.83 millionViewN/AView Earnings Details
4/26/2013Q3 2013($0.15)($0.02)$11.94 million$25.00 millionViewN/AView Earnings Details
1/25/2013Q2 2013($0.25)($0.29)$6.02 million$2.60 millionViewN/AView Earnings Details
10/26/2012Q113($0.25)($0.30)$4.10 million$4.10 millionViewN/AView Earnings Details
8/3/2012($0.30)($0.29)ViewN/AView Earnings Details
4/27/2012($0.26)($0.24)ViewN/AView Earnings Details
1/27/2012($0.22)($0.17)ViewN/AView Earnings Details
10/27/2011($0.22)($0.26)ViewN/AView Earnings Details
8/3/2011($0.24)($0.23)ViewN/AView Earnings Details
4/28/2011Q1 2011($0.23)($0.22)ViewN/AView Earnings Details
1/27/2011Q4 2010($0.22)($0.21)ViewN/AView Earnings Details
10/28/2010Q3 2010($0.23)($0.19)ViewN/AView Earnings Details
8/4/2010Q2 2010($0.24)($0.21)ViewN/AView Earnings Details
4/29/2010Q1 2010($0.23)($0.21)ViewN/AView Earnings Details
1/28/2010Q4 2009($0.21)($0.23)ViewN/AView Earnings Details
10/29/2009Q3 2009($0.20)($0.22)ViewN/AView Earnings Details
8/6/2009Q2 2009($0.17)($0.21)ViewN/AView Earnings Details
4/30/2009Q1 2009($0.10)($0.09)ViewN/AView Earnings Details
1/29/2009Q4 2008($0.15)($0.14)ViewN/AView Earnings Details
10/27/2008Q3 2008($0.21)($0.19)ViewN/AView Earnings Details
8/7/2008Q2 2008($0.25)($0.27)ViewN/AView Earnings Details
5/1/2008Q1 2008($0.21)($0.30)ViewN/AView Earnings Details
1/31/2008Q4 2007($0.11)($0.15)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

ImmunoGen (NASDAQ:IMGN) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

ImmunoGen (NASDAQ IMGN) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 6.51%
Institutional Ownership Percentage: 77.65%
Insider Trading History for ImmunoGen (NASDAQ:IMGN)
Insider Trading History for ImmunoGen (NASDAQ:IMGN)

ImmunoGen (NASDAQ IMGN) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/16/2018Daniel M JuniusDirectorSell25,000$12.02$300,500.00209,987View SEC Filing  
3/15/2018David Brannon JohnstonCFOSell10,000$11.53$115,300.00190,690View SEC Filing  
2/21/2018David Brannon JohnstonCFOSell21,060$10.87$228,922.20180,690View SEC Filing  
2/21/2018Mark J EnyedyCEOSell67,717$10.87$736,083.79532,383View SEC Filing  
2/21/2018Richard J GregoryVPSell34,486$10.88$375,207.68239,094View SEC Filing  
2/20/2018Daniel M JuniusDirectorSell25,000$11.68$292,000.00196,700View SEC Filing  
2/13/2018Daniel M JuniusDirectorSell46,667$10.01$467,136.67243,367View SEC Filing  
1/8/2018Richard J GregoryVPSell2,904$6.64$19,282.56273,577View SEC Filing  
9/15/2017Craig BarrowsVPSell37,050$6.81$252,310.5051,100View SEC Filing  
9/13/2017Craig BarrowsVPSell14,600$6.95$101,470.0051,100View SEC Filing  
12/15/2016Mark Alan GoldbergDirectorBuy20,000$1.80$36,000.0023,800View SEC Filing  
11/8/2016Mark J EnyedyCEOBuy25,000$1.83$45,750.00100,100View SEC Filing  
11/2/2016Craig BarrowsInsiderBuy10,000$1.71$17,100.0031,100View SEC Filing  
11/2/2016Richard J GregoryVPBuy16,600$1.78$29,548.0039,231View SEC Filing  
2/1/2016John LambertEVPSell3,889$8.22$31,967.58106,857View SEC Filing  
1/8/2016Richard J GregoryVPSell2,369$11.10$26,295.9022,631View SEC Filing  
1/4/2016Daniel M. JuniusCEOSell5,416$13.17$71,328.72169,615View SEC Filing  
1/4/2016John LambertEVPSell3,889$13.20$51,334.80106,857View SEC Filing  
12/1/2015Daniel M. JuniusCEOSell5,416$13.11$71,003.76170,618View SEC Filing  
12/1/2015John LambertEVPSell3,889$13.11$50,984.79106,857View SEC Filing  
11/27/2015Charles Q MorrisVPSell5,170$14.00$72,380.0027,090View SEC Filing  
11/17/2015Dean J MitchellDirectorBuy10,000$12.51$125,100.0010,000View SEC Filing  
11/2/2015Daniel M. JuniusCEOSell5,497$12.00$65,964.00159,812View SEC Filing  
11/2/2015John LambertEVPSell3,889$11.73$45,617.97106,857View SEC Filing  
10/29/2015Daniel M. JuniusCEOSell5,335$12.01$64,073.35154,115View SEC Filing  
10/1/2015John LambertEVPSell3,889$9.55$37,139.95106,857View SEC Filing  
9/17/2015David Brannon JohnstonCFOSell5,000$15.00$75,000.00View SEC Filing  
9/1/2015Daniel M. JuniusCEOSell5,416$13.15$71,220.40154,115View SEC Filing  
9/1/2015John LambertEVPSell3,889$13.16$51,179.24106,857View SEC Filing  
7/1/2015Daniel M JuniusCEOSell5,416$14.34$77,665.44View SEC Filing  
7/1/2015John LambertEVPSell3,888$14.34$55,753.92View SEC Filing  
6/15/2015Nicole OnettoDirectorSell3,211$13.86$44,504.46View SEC Filing  
6/1/2015John LambertEVPSell15,000$11.78$176,700.00View SEC Filing  
5/7/2015Daniel M JuniusCEOSell1,215$8.02$9,744.30View SEC Filing  
5/1/2015John LambertEVPSell10,000$8.32$83,200.00View SEC Filing  
11/28/2014Charles Q MorrisVPSell5,240$10.40$54,496.00View SEC Filing  
3/17/2014Daniel JuniusCEOSell15,000$16.40$246,000.0080,636View SEC Filing  
2/26/2014Charles MorrisVPSell6,936$17.35$120,339.6037,500View SEC Filing  
2/20/2014Charles MorrisVPSell13,672$17.10$233,791.2037,500View SEC Filing  
2/18/2014Daniel JuniusCEOSell15,000$16.26$243,900.0080,636View SEC Filing  
2/3/2014John LambertEVPSell4,375$14.90$65,187.50106,857View SEC Filing  
1/22/2014Charles MorrisVPSell7,138$17.00$121,346.0037,500View SEC Filing  
1/10/2014Theresa WingroveVPSell6,250$15.04$94,000.00View SEC Filing  
1/2/2014John LambertEVPSell4,375$14.53$63,568.75106,857View SEC Filing  
12/10/2013Daniel JuniusCEOSell15,000$15.11$226,650.0073,336View SEC Filing  
12/2/2013John LambertEVPSell4,375$14.70$64,312.50106,857View SEC Filing  
11/26/2013Charles MorrisVPSell12,500$13.75$171,875.0037,500View SEC Filing  
11/1/2013John LambertEVPSell4,375$16.41$71,793.75View SEC Filing  
9/10/2013Gregory D PerryCFOSell18,337$17.82$326,765.34View SEC Filing  
9/3/2013Daniel JuniusCEOSell16,667$16.43$273,838.8173,336View SEC Filing  
9/3/2013John LambertEVPSell4,375$16.45$71,968.75106,857View SEC Filing  
8/1/2013Daniel M JuniusCEOSell16,667$19.21$320,173.07View SEC Filing  
8/1/2013John LambertEVPSell4,375$19.21$84,043.75View SEC Filing  
7/11/2013James J O'learyVPSell35,000$19.02$665,700.00View SEC Filing  
7/3/2013Daniel M JuniusCEOSell16,667$17.31$288,505.77View SEC Filing  
7/1/2013John LambertEVPSell4,375$16.80$73,500.00View SEC Filing  
6/3/2013John LambertEVPSell11,250$17.20$193,500.00View SEC Filing  
5/24/2013James J O'learyVPSell28,900$18.11$523,379.00View SEC Filing  
5/1/2013John LambertEVPSell11,250$15.56$175,050.00View SEC Filing  
4/11/2013James J O'learyVPSell31,100$17.37$540,207.00View SEC Filing  
11/8/2012Mark Alan GoldbergDirectorBuy3,000$11.27$33,810.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

ImmunoGen (NASDAQ IMGN) News Headlines

Source:
DateHeadline
Cowen Reaffirms "Hold" Rating for ImmunoGen (IMGN)Cowen Reaffirms "Hold" Rating for ImmunoGen (IMGN)
www.americanbankingnews.com - May 17 at 4:33 PM
ImmunoGen (IMGN) PT Set at $18.00 by HC WainwrightImmunoGen (IMGN) PT Set at $18.00 by HC Wainwright
www.americanbankingnews.com - May 17 at 2:59 PM
ImmunoGens mirventuximab soravtansine shows positive effect in early-stage ovarian cancer studyImmunoGen's mirventuximab soravtansine shows positive effect in early-stage ovarian cancer study
seekingalpha.com - May 17 at 2:31 PM
BRIEF-Immunogen Announces Positive Findings From Forward 2 Study Of Mirvetuximab Soravtansine Combination ...BRIEF-Immunogen Announces Positive Findings From Forward 2 Study Of Mirvetuximab Soravtansine Combination ...
www.reuters.com - May 17 at 10:02 AM
Immunogen (IMGN) Reports Positive Findings from the FORWARD II Study of Mirvetuximab Soravtansine Combination ...Immunogen (IMGN) Reports Positive Findings from the FORWARD II Study of Mirvetuximab Soravtansine Combination ...
www.streetinsider.com - May 17 at 10:02 AM
ImmunoGen (IMGN) option implied volatility, says to present data from FORWARD II trial at ASCOImmunoGen (IMGN) option implied volatility, says to present data from FORWARD II trial at ASCO
www.streetinsider.com - May 17 at 10:02 AM
Form 8-K IMMUNOGEN INC For: May 16Form 8-K IMMUNOGEN INC For: May 16
www.streetinsider.com - May 17 at 10:02 AM
ImmunoGen Announces Positive Findings from the FORWARD II Study of Mirvetuximab Soravtansine Combination ...ImmunoGen Announces Positive Findings from the FORWARD II Study of Mirvetuximab Soravtansine Combination ...
www.businesswire.com - May 17 at 10:02 AM
ImmunoGen Announces Positive Findings from the FORWARD II Study of Mirvetuximab Soravtansine Combination Regimens with Avastin® and Carboplatin in Ovarian CancerImmunoGen Announces Positive Findings from the FORWARD II Study of Mirvetuximab Soravtansine Combination Regimens with Avastin® and Carboplatin in Ovarian Cancer
finance.yahoo.com - May 17 at 10:02 AM
Analyzing ImmunoGen (IMGN) & AnaptysBio (ANAB)Analyzing ImmunoGen (IMGN) & AnaptysBio (ANAB)
www.americanbankingnews.com - May 15 at 5:19 AM
ImmunoGen (IMGN) Given Average Rating of "Buy" by AnalystsImmunoGen (IMGN) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - May 15 at 1:40 AM
Synaffix Further Strengthens Its Scientific Advisory Board with the Addition of John Lambert PhD, Former CSO of ...Synaffix Further Strengthens Its Scientific Advisory Board with the Addition of John Lambert PhD, Former CSO of ...
www.businesswire.com - May 14 at 11:12 AM
ImmunoGen (IMGN) Lowered to Buy at BidaskClubImmunoGen (IMGN) Lowered to Buy at BidaskClub
www.americanbankingnews.com - May 10 at 12:36 AM
ImmunoGen: An Extremely Promising ADC Therapeutic InnovatorImmunoGen: An Extremely Promising ADC Therapeutic Innovator
seekingalpha.com - May 9 at 4:10 PM
Q2 2018 Earnings Estimate for ImmunoGen Issued By William Blair (IMGN)Q2 2018 Earnings Estimate for ImmunoGen Issued By William Blair (IMGN)
www.americanbankingnews.com - May 9 at 8:41 AM
$15.00 Million in Sales Expected for ImmunoGen (IMGN) This Quarter$15.00 Million in Sales Expected for ImmunoGen (IMGN) This Quarter
www.americanbankingnews.com - May 9 at 4:44 AM
ImmunoGen Presses ForwardImmunoGen Presses Forward
www.fool.com - May 8 at 8:49 PM
ImmunoGen (IMGN) Q1 Loss Wider Than Expected, Revenues BeatImmunoGen (IMGN) Q1 Loss Wider Than Expected, Revenues Beat
finance.yahoo.com - May 7 at 10:12 AM
ImmunoGen (IMGN) Expected to Announce Earnings of -$0.28 Per ShareImmunoGen (IMGN) Expected to Announce Earnings of -$0.28 Per Share
www.americanbankingnews.com - May 7 at 3:14 AM
Edited Transcript of IMGN earnings conference call or presentation 4-May-18 12:00pm GMTEdited Transcript of IMGN earnings conference call or presentation 4-May-18 12:00pm GMT
finance.yahoo.com - May 5 at 10:06 AM
ImmunoGen (IMGN) Releases Quarterly  Earnings Results, Misses Estimates By $0.06 EPSImmunoGen (IMGN) Releases Quarterly Earnings Results, Misses Estimates By $0.06 EPS
www.americanbankingnews.com - May 4 at 8:33 PM
ImmunoGens (IMGN) CEO Mark Enyedy on Q1 2018 Results - Earnings Call TranscriptImmunoGen's (IMGN) CEO Mark Enyedy on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 4 at 4:10 PM
Form 8-K IMMUNOGEN INC For: May 04Form 8-K IMMUNOGEN INC For: May 04
www.streetinsider.com - May 4 at 9:45 AM
ImmunoGen: 1Q Earnings SnapshotImmunoGen: 1Q Earnings Snapshot
finance.yahoo.com - May 4 at 9:45 AM
ImmunoGen (IMGN) Q1 Loss Wider, Revenues BeatImmunoGen (IMGN) Q1 Loss Wider, Revenues Beat
finance.yahoo.com - May 4 at 9:45 AM
ImmunoGen Announces Webcast of Presentation at Deutsche Banks 43ImmunoGen Announces Webcast of Presentation at Deutsche Bank's 43
www.businesswire.com - May 3 at 9:47 AM
ImmunoGen Announces Webcast of Presentation at Deutsche Bank’s 43rd Annual Health Care ConferenceImmunoGen Announces Webcast of Presentation at Deutsche Bank’s 43rd Annual Health Care Conference
finance.yahoo.com - May 3 at 9:47 AM
ImmunoGen (IMGN) Stock Rating Upgraded by BidaskClubImmunoGen (IMGN) Stock Rating Upgraded by BidaskClub
www.americanbankingnews.com - May 2 at 1:10 PM
What's in Store for ImmunoGen (IMGN) This Earnings Season?What's in Store for ImmunoGen (IMGN) This Earnings Season?
finance.yahoo.com - April 30 at 4:07 PM
Form DEF 14A IMMUNOGEN INC For: Jun 20Form DEF 14A IMMUNOGEN INC For: Jun 20
www.streetinsider.com - April 30 at 10:47 AM
Whats in Store for ImmunoGen (IMGN) This Earnings Season?What's in Store for ImmunoGen (IMGN) This Earnings Season?
www.zacks.com - April 30 at 10:47 AM
ImmunoGen (IMGN) Upgraded by ValuEngine to "Hold"ImmunoGen (IMGN) Upgraded by ValuEngine to "Hold"
www.americanbankingnews.com - April 27 at 10:20 PM
ImmunoGen (IMGN) Given Buy Rating at Canaccord GenuityImmunoGen (IMGN) Given Buy Rating at Canaccord Genuity
www.americanbankingnews.com - April 27 at 9:16 PM
Why ImmunoGen, Inc. Stock Is on the Rise TodayWhy ImmunoGen, Inc. Stock Is on the Rise Today
www.fool.com - April 27 at 1:42 PM
BRIEF-Immunogen Completes Interim Analysis For Forward I Phase 3 Trial Of Mirvetuximab SoravtansineBRIEF-Immunogen Completes Interim Analysis For Forward I Phase 3 Trial Of Mirvetuximab Soravtansine
www.reuters.com - April 27 at 10:37 AM
ImmunoGen Announces Successful Completion of Interim Analysis for FORWARD I Phase 3 Trial of Mirvetuximab ...ImmunoGen Announces Successful Completion of Interim Analysis for FORWARD I Phase 3 Trial of Mirvetuximab ...
www.businesswire.com - April 27 at 10:37 AM
ImmunoGen Announces Successful Completion of Interim Analysis for FORWARD I Phase 3 Trial of Mirvetuximab Soravtansine in Platinum-Resistant Ovarian CancerImmunoGen Announces Successful Completion of Interim Analysis for FORWARD I Phase 3 Trial of Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer
finance.yahoo.com - April 27 at 10:37 AM
Here’s Why The Immunogen News Is Important For The CompanyHere’s Why The Immunogen News Is Important For The Company
finance.yahoo.com - April 27 at 10:37 AM
ImmunoGen (IMGN) Scheduled to Post Earnings on FridayImmunoGen (IMGN) Scheduled to Post Earnings on Friday
www.americanbankingnews.com - April 27 at 1:34 AM
Form 3 IMMUNOGEN INC For: Apr 23 Filed by: McKee Blaine H.Form 3 IMMUNOGEN INC For: Apr 23 Filed by: McKee Blaine H.
www.streetinsider.com - April 26 at 9:53 AM
ImmunoGen (IMGN) Given a $18.00 Price Target at HC WainwrightImmunoGen (IMGN) Given a $18.00 Price Target at HC Wainwright
www.americanbankingnews.com - April 26 at 8:00 AM
ImmunoGen (IMGN) Short Interest UpdateImmunoGen (IMGN) Short Interest Update
www.americanbankingnews.com - April 26 at 2:22 AM
ImmunoGen Appoints Blaine McKee as Executive Vice President and Chief Business OfficerImmunoGen Appoints Blaine McKee as Executive Vice President and Chief Business Officer
finance.yahoo.com - April 25 at 10:27 AM
$15.29 Million in Sales Expected for ImmunoGen (IMGN) This Quarter$15.29 Million in Sales Expected for ImmunoGen (IMGN) This Quarter
www.americanbankingnews.com - April 22 at 4:56 AM
ImmunoGen (IMGN) Given a $5.00 Price Target by Royal Bank of Canada AnalystsImmunoGen (IMGN) Given a $5.00 Price Target by Royal Bank of Canada Analysts
www.americanbankingnews.com - April 20 at 2:25 PM
ImmunoGen Announces Conference Call to Discuss Its First Quarter 2018 Operating ResultsImmunoGen Announces Conference Call to Discuss Its First Quarter 2018 Operating Results
finance.yahoo.com - April 20 at 10:03 AM
ImmunoGen (IMGN) Receives Consensus Rating of "Hold" from BrokeragesImmunoGen (IMGN) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - April 20 at 1:26 AM
ImmunoGen (IMGN) Expected to Post Earnings of -$0.27 Per ShareImmunoGen (IMGN) Expected to Post Earnings of -$0.27 Per Share
www.americanbankingnews.com - April 20 at 1:26 AM
Stock Traders Buy High Volume of ImmunoGen Put Options (IMGN)Stock Traders Buy High Volume of ImmunoGen Put Options (IMGN)
www.americanbankingnews.com - April 19 at 8:32 AM
Are Options Traders Betting on a Big Move in ImmunoGen (IMGN) Stock? April 18, 2018Are Options Traders Betting on a Big Move in ImmunoGen (IMGN) Stock? April 18, 2018
www.zacks.com - April 18 at 10:06 AM

SEC Filings

ImmunoGen (NASDAQ:IMGN) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

ImmunoGen (NASDAQ:IMGN) Income Statement, Balance Sheet and Cash Flow Statement

Chart

ImmunoGen (NASDAQ IMGN) Stock Chart for Friday, May, 25, 2018

Loading chart…

This page was last updated on 5/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.